Edition:
India

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

36.25USD
15 Dec 2017
Change (% chg)

$-3.15 (-7.99%)
Prev Close
$39.40
Open
$37.60
Day's High
$38.00
Day's Low
$35.30
Volume
1,198,476
Avg. Vol
228,481
52-wk High
$45.85
52-wk Low
$13.35

Latest Key Developments (Source: Significant Developments)

Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING.  Full Article

Global Blood Therapeutics To Sell $100 Mln In Public Offering Of Shares
Friday, 15 Dec 2017 

Dec 14 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC - ANNOUNCED AN AGREEMENT TO SELL $100.0 MILLION IN SHARES OF ITS COMMON STOCK.GLOBAL BLOOD THERAPEUTICS - TO USE NET PROCEEDS FROM OFFERING TO FUND CLINICAL DEVELOPMENT OF VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE.  Full Article

Global Blood Therapeutics posts Q3 loss per share $0.66
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Global Blood Therapeutics Inc :Global Blood Therapeutics reports recent business progress and provides third quarter 2017 financial results.Q3 loss per share $0.66.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.Global Blood Therapeutics - continue to expect cash,cash equivalents,marketable securities to be enough to take co to top-line data in hope study​.Global Blood Therapeutics Inc - ‍qtrly cash, cash equivalents, marketable securities $259.4 million at Sept 30, 2017 versus $197.3 million at Dec 31, 2016​.  Full Article

Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Global Blood Therapeutics Inc ::Global Blood Therapeutics announces approval of first-in-class “voxelotor” as nonproprietary name for gbt440.Global Blood Therapeutics Inc - ‍world Health Organization has approved "voxelotor" as international nonproprietary name for gbt440​.  Full Article

Global Blood Therapeutics announces discontinuation of IPF program
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Global Blood Therapeutics Inc :Global Blood Therapeutics announces discontinuation of Idiopathic Pulmonary Fibrosis (IPF) program​.Says discontinuation of its GBT440 program for treatment of idiopathic pulmonary fibrosis​.Says ‍decision to discontinue is based on results from 3 proof-of-concept studies including phase 1 study in healthy volunteers.Says ‍decision to discontinue is also based on two phase 2A studies in patients with ipf called GBT440-006 and Zephyr​.Says data from proof-of-concept studies did not demonstrate sufficient overall clinical benefit to justify continuing IPF program.Says ‍remain on track to announce top-line clinical trial results from phase 3 Hope study in H1 2019 ​.Says ‍GBT440 was generally well tolerated across all three studies​.  Full Article

Global Blood Therapeutics Q2 loss per share $0.58
Thursday, 11 Aug 2016 

Global Blood Therapeutics Inc : Q2 loss per share $0.58 . Global blood therapeutics reports recent business progress and provides second quarter 2016 financial results .Q2 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.  Full Article

Global Blood Therapeutics closes of public offering of common stock
Saturday, 25 Jun 2016 

Global Blood Therapeutics Inc : Says public offering of 6.40 million common shares priced at $18.75 per share .Global Blood Therapeutics announces closing of public offering of common stock.  Full Article

Global Blood Therapeutics announces pricing of public offering of common stock
Tuesday, 21 Jun 2016 

Global Blood Therapeutics Inc : Says public offering of 6.40 million common shares priced at $18.75 per share .Global blood therapeutics announces pricing of public offering of common stock.  Full Article

Global Blood Therapeutics announces pricing of public offering of common stock
Tuesday, 21 Jun 2016 

Global Blood Therapeutics Inc : Says public offering of 6.40 million common shares priced at $18.75 per share .Global blood therapeutics announces pricing of public offering of common stock.  Full Article

Global Blood says commenced underwritten public offering of $100 mln shares
Monday, 20 Jun 2016 

Global Blood Therapeutics Inc : Commenced an underwritten public offering of $100 million of shares of its common stock .Global blood therapeutics announces proposed public offering of common stock.  Full Article

BRIEF-Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering

* GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING Source text for Eikon: Further company coverage: